GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » Median PS Value

EUCRU (Eucrates Biomedical Acquisition) Median PS Value : $0.00 (As of Dec. 15, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Eucrates Biomedical Acquisition Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Eucrates Biomedical Acquisition's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 was $. Eucrates Biomedical Acquisition's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.

As of today (2024-12-15), Eucrates Biomedical Acquisition's share price is $10.02. Eucrates Biomedical Acquisition's Median PS Value is $0.00. Therefore, Eucrates Biomedical Acquisition's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Eucrates Biomedical Acquisition's Median PS Value or its related term are showing as below:

EUCRU's Price-to-Median-PS-Value is not ranked *
in the Diversified Financial Services industry.
Industry Median: 1.1
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Eucrates Biomedical Acquisition Median PS Value Historical Data

The historical data trend for Eucrates Biomedical Acquisition's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eucrates Biomedical Acquisition Median PS Value Chart

Eucrates Biomedical Acquisition Annual Data
Trend Dec20 Dec21 Dec22
Median PS Value
- - -

Eucrates Biomedical Acquisition Quarterly Data
Aug20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Eucrates Biomedical Acquisition's Median PS Value

For the Shell Companies subindustry, Eucrates Biomedical Acquisition's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eucrates Biomedical Acquisition's Price-to-Median-PS-Value Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Eucrates Biomedical Acquisition's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Eucrates Biomedical Acquisition's Price-to-Median-PS-Value falls into.



Eucrates Biomedical Acquisition Median PS Value Calculation

Eucrates Biomedical Acquisition's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=*
=0.00

10-Year Median PS Ratio is .
Eucrates Biomedical Acquisition's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eucrates Biomedical Acquisition  (NAS:EUCRU) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Eucrates Biomedical Acquisition's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=10.02/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eucrates Biomedical Acquisition Median PS Value Related Terms

Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Eucrates Biomedical Acquisition Business Description

Traded in Other Exchanges
N/A
Address
250 West 55th Street, Suite 13D, New York, NY, USA, 10019
Website
Eucrates Biomedical Acquisition Corp is a blank check company.
Executives
Stelios Papadopoulos director, 10 percent owner 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
William I Campbell director 270 PARK AVENUE, NEW YORK NY 10017
Nina B. Shapiro director 2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538
Parag Saxena director, 10 percent owner, officer: Chief Executive Officer 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Daphne Karydas director 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Atanuu Agarrwal officer: Vice President 250 WEST 55TH STREET, NEW YORK NY 10019
Gonzalo Cordova officer: Chief Financial Officer 250 WEST 55TH STREET, NEW YORK NY 10019
Eucrates Llc 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Shrikant Sathe officer: Senior Vice President C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Evangelos Vergetis director, officer: President, COO C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Amitabh Singhal director C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019

Eucrates Biomedical Acquisition Headlines